A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine

Journal of Psychiatric Practice
Moshe KotlerAndreas Schreiner

Abstract

The goal of this study was to explore the tolerability, safety, and treatment response of switching from oral olanzapine to paliperidone extended release (ER). Adult patients with nonacute schizophrenia who had been treated unsuccessfully with oral olanzapine were switched to flexible doses of paliperidone ER (3 to 12 mg/d). The primary efficacy outcome was a ≥ 20% improvement in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to endpoint for patients who switched medications because of lack of efficacy with olanzapine and noninferiority versus previous olanzapine treatment (mean endpoint change in PANSS total scores vs. baseline of ≤ 5 points) for patients who switched for reasons other than lack of efficacy. Safety and tolerability were assessed by monitoring adverse events, extrapyramidal symptoms, and weight change. Of 396 patients, 65.2% were men, mean age was 40.0 ± 12.0 years, and 75.5% had paranoid schizophrenia. Among the patients whose main reason for switching was lack of efficacy, an improvement in the PANSS total score of ≥ 20% occurred in 57.4% of patients. Noninferiority was confirmed for each subgroup of patients whose main reason for switching was something other than lack of efficacy. P...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Nov 1, 1994·The Journal of Nervous and Mental Disease·J P LindenmayerS Grochowski
Jun 14, 2005·Schizophrenia Research·Guy Chouinard, Howard C Margolese
Jun 29, 2005·Schizophrenia Research·Stefan LeuchtRolf R Engel
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan Leucht, Rolf R Engel
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtRolf R Engel
Jul 18, 2006·The Journal of Clinical Psychiatry·John M Kane
Oct 7, 2006·Current Medical Research and Opinion·Robert ConleyGayatri Sathyan
Oct 24, 2007·Schizophrenia Research·Stephen Z LevineStefan Leucht
Jun 12, 2008·International Clinical Psychopharmacology·Carla M CanusoGeorge M Simpson
Nov 7, 2008·Biological Psychiatry·W Wolfgang FleischhackerWilliam H Carson
Jul 31, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·G MarcheseL Pani
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
Apr 3, 2010·Psychiatric Services : a Journal of the American Psychiatric Association·Suzanne M HardemanMeera Narasimhan
May 26, 2010·International Journal of Clinical Pharmacology and Therapeutics·M P JonesK Trakas
Apr 27, 2012·Neuropsychiatric Disease and Treatment·Haya Ascher-SvanumKatarina Kelin
Jul 15, 2015·Journal of Psychiatric Practice·Sheldon H PreskornMadhukar Trivedi

❮ Previous
Next ❯

Citations

Mar 30, 2021·Expert Opinion on Drug Safety·Renato de FilippisMaria Rosaria Anna Muscatello

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.